Jeff Zonder

International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

S. Vincent Rajkumar, JL Harousseau, Brian G.M. Durie et al. · Institutional Research Information System University of Turin (University of Turin) · 2011 · 131 citations · Full text

Hematological Malignancy, Oncology, Consensus Recommendations +7

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial

Paul G. Richardson, J. Wolf, Andrzej Jakubowiak et al. · Journal of Clinical Oncology · 2011 · 119 citations · Full text

Perifosine Plus Bortezomib, Hematological Malignancy, Relapsed/refractory Mm +13

Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes

Anwar N. Mohamed, Gail Bentley, Michelle Bonnett et al. · American Journal of Hematology · 2007 · 42 citations

Karyotype Imaging, Hematological Malignancy, Cytogenetics +15

Phase II study of carfilzomib in patients with relapsed/refractory multiple myeloma and renal insufficiency.

A. Badros, Ravi Vij, Thomas G Martin et al. · Journal of Clinical Oncology · 2010 · 21 citations

Immunology, Phase Ii Study, Pharmacotherapy +24

A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results

Jeff Zonder, John J. Crowley, Vanessa Bolejack et al. · Journal of Clinical Oncology · 2008 · 19 citations

Cytogenetics, Pathology, Cytogenetic Abnormalities +16